A
Arnold Brossi
Researcher at University of North Carolina at Chapel Hill
Publications - 39
Citations - 2409
Arnold Brossi is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Acetylcholinesterase & Cytotoxicity. The author has an hindex of 22, co-authored 39 publications receiving 2210 citations.
Papers
More filters
Journal ArticleDOI
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
Nigel H. Greig,Tadanobu Utsuki,Tadanobu Utsuki,Donald K. Ingram,Yue Wang,Giancarlo Pepeu,Carla Scali,Qian Sheng Yu,Jacek Mamczarz,Harold W. Holloway,Tony Giordano,Demao Chen,Katsutoshi Furukawa,Kumar Sambamurti,Arnold Brossi,Debomoy K. Lahiri +15 more
TL;DR: In rats, cymserine analogs caused long-term inhibition of brain BChE and elevated extracellular ACh levels, without inhibitory effects on acetylcholinesterase, and improved the cognitive performance of aged rats.
Journal ArticleDOI
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Yazhou Li,Tracy Ann Perry,Mark S. Kindy,Brandon K. Harvey,David Tweedie,Harold W. Holloway,Kathleen Powers,Hui Shen,Josephine M. Egan,Kumar Sambamurti,Arnold Brossi,Debomoy K. Lahiri,Mark P. Mattson,Barry J. Hoffer,Yun Wang,Nigel H. Greig +15 more
TL;DR: It is demonstrated that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for exendin-4 in the treatment of stroke and PD.
Journal ArticleDOI
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Nigel H. Greig,Kumar Sambamurti,Qian Sheng Yu,Arnold Brossi,Gosse Bruinsma,Debomoy K. Lahiri +5 more
TL;DR: Clinical studies reveal that (-)-phenserine had a favorable safety and pharmacological profile, produced significant improvements in cognitive function and was well tolerated in patients with AD treated for 12 weeks, and randomized, double-blind, placebo-controlled Phase III studies assessing the efficacy, safety/tolerability and potential disease-modifying effects of (-)- Phenserine in Patients with AD are currently ongoing.
Journal Article
Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases.
TL;DR: Results do show that the structure of physostigmine can be changed significantly while retaining biological activity and the phenyl substitution appears to increase greatly the selectivity of the compound for AChE.
Journal ArticleDOI
Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis.
Shun Xiang Zhang,Jun Feng,Sheng-Chu Kuo,Arnold Brossi,Ernest Hamel,Alexander Tropsha,Kuo Hsiung Lee +6 more
TL;DR: The conventional CoMFA model with the highest predictive q(2) (0.546) was analyzed in detail in terms of underlying structure-activity relationships and was confirmed by successful activity prediction for a test set of 53 compounds with known potencies as inhibitors of tubulin polymerization.